Pharmacogenomics-Supported Psychotropic Prescribing Trial
Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba.
| Condition(s) | Mental Disorder, Pharmacogenetics, Adverse Drug Reaction (ADR), Effectiveness |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba. |
| Who can participate | Inclusion Criteria: * Aged 18 years or older * The initiation, change, dose adjustment, or augmentation of psychotropic medication(s) is indicated * The treating clinician thinks PGx testing can benefit and refers the patient to the study Exclusion Criteria: * Unwillingness to donate saliva samples for genetic analysis * History of liver or bone marrow (hematopoietic cell) transplantation * PGx testing results are already available * No personal health identification number (PHIN) is available |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University of Manitoba |
| Locations | Winnipeg, Manitoba, Canada; Winnipeg, Manitoba, Canada |
| Start date | 2025-07-01 |
| NCT ID | NCT06929533 |
| Official listing | https://clinicaltrials.gov/study/NCT06929533 |